A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

1,017

Participants

Timeline

Start Date

September 1, 2014

Primary Completion Date

May 25, 2015

Study Completion Date

June 15, 2015

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Umeclidinium

Umeclidinium 62.5 mcg once daily in the morning via nDPI

DRUG

Umeclidinium matching placebo

Umeclidinium matching placebo once daily in the morning via nDPI

DRUG

Tiotropium

Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler

DRUG

Tiotropium matching placebo

Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler

Trial Locations (99)

1459

GSK Investigational Site, Boksburg

2129

GSK Investigational Site, Vrededorp

2400

GSK Investigational Site, København NV

2650

GSK Investigational Site, Hvidovre

4001

GSK Investigational Site, Durban

6001

GSK Investigational Site, Port Elizabeth

6014

GSK Investigational Site, Korsten

7130

GSK Investigational Site, Somerset West

7530

GSK Investigational Site, Bellville

7700

GSK Investigational Site, Mowbray

8000

GSK Investigational Site, Aarhus C

9460

GSK Investigational Site, Welkom

10117

GSK Investigational Site, Berlin

10717

GSK Investigational Site, Berlin

13156

GSK Investigational Site, Berlin

20138

GSK Investigational Site, Milan

29303

GSK Investigational Site, Spartanburg

36038

GSK Investigational Site, Poltava

37024

GSK Investigational Site, Negrar

37100

GSK Investigational Site, Tours

39140

GSK Investigational Site, Bletterans

44277

GSK Investigational Site, Nantes

47838

GSK Investigational Site, Riccione (RN)

49074

GSK Investigational Site, Dnipropetrovsk

50096

GSK Investigational Site, Kryvyi Rig

56124

GSK Investigational Site, Pisa

59690

GSK Investigational Site, Vieux-Condé

60020

GSK Investigational Site, Torrette (AN)

60389

GSK Investigational Site, Frankfurt am Main

61002

GSK Investigational Site, Kharkiv

61039

GSK Investigational Site, Kharkiv

63110

GSK Investigational Site, Rodgau

63263

GSK Investigational Site, Neu-Isenburg

63739

GSK Investigational Site, Aschaffenburg

65187

GSK Investigational Site, Wiesbaden

69050

GSK Investigational Site, Zaporizhzhia

83000

GSK Investigational Site, Toulon

100379

GSK Investigational Site, Ploieşti

117997

GSK Investigational Site, Moscow

153000

GSK Investigational Site, Arkhangelsk

163001

GSK Investigational Site, Arkhangelsk

194354

GSK Investigational Site, Saint Petersburg

194356

GSK Investigational Site, Saint Petersburg

196084

GSK Investigational Site, Saint Petersburg

197706

GSK Investigational Site, Sestroretsk

198216

GSK Investigational Site, Saint Petersburg

198260

GSK Investigational Site, Saint Petersburg

300310

GSK Investigational Site, Timișoara

330084

GSK Investigational Site, Deva

354057

GSK Investigational Site, Sochi

355017

GSK Investigational Site, Stavropol

426063

GSK Investigational Site, Izhevsk

450071

GSK Investigational Site, Ufa

505100

GSK Investigational Site, Codlea

600023

GSK Investigational Site, Vladimir

600252

GSK Investigational Site, Bacau

617507

GSK Investigational Site, Comuna Alexandru Cel Bun

620043

GSK Investigational Site, Focşani

630102

GSK Investigational Site, Novosibirsk

634050

GSK Investigational Site, Tomsk

650002

GSK Investigational Site, Kemerovo

664003

GSK Investigational Site, Irkutsk

800189

GSK Investigational Site, Galati

810003

GSK Investigational Site, Brăila

2341131

GSK Investigational Site, Valparaíso

4270918

GSK Investigational Site, Talcahuano

7500692

GSK Investigational Site, Santiago

7860406

GSK Investigational Site, Santiago

8360160

GSK Investigational Site, Santiago

C1425BEN

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

R2K 3S8

GSK Investigational Site, Winnipeg

A1A 3R5

GSK Investigational Site, St. John's

B2N 1L2

GSK Investigational Site, Truro

P3E 1H5

GSK Investigational Site, Greater Sudbury

M3J 2C5

GSK Investigational Site, Toronto

M5G 1N8

GSK Investigational Site, Toronto

H2R 1V6

GSK Investigational Site, Montreal

G1V 4G5

GSK Investigational Site, Québec

G1W 4R4

GSK Investigational Site, Québec

J6E 2B4

GSK Investigational Site, Saint-Charles-Borromée

J1H 5N4

GSK Investigational Site, Sherbrooke

DK-5000

GSK Investigational Site, Odense

01069

GSK Investigational Site, Dresden

06682

GSK Investigational Site, Teuchern

04626

GSK Investigational Site, Schmölln

030303

GSK Investigational Site, Bucharest

656 045

GSK Investigational Site, Barnaul

115 280

GSK Investigational Site, Moscow

Unknown

GSK Investigational Site, Saint Petersburg

0040

GSK Investigational Site, Lynnwood Ridge, Pretoria

420-767

GSK Investigational Site, Bucheon-Si, Gyeonggi-Do

130-709

GSK Investigational Site, Seoul

134-814

GSK Investigational Site, Seoul

136-705

GSK Investigational Site, Seoul

156-707

GSK Investigational Site, Seoul

220-701

GSK Investigational Site, Wonju-si, Gangwon-do

03680

GSK Investigational Site, Kiev

03038

GSK Investigational Site, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02207829 - A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter